December 2016
-
Lonza has announced that it will invest CHf 85 million (~$94 million) at 8 of its Capsugel manufacturing sites around the world to expand its capsule manufacturing capacity by 15%, or 30 billion capsules per… Read more . . .
-
According to AstraZeneca, the EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the company’s Trixeo Aerosphere formoterol fumarate/ glycopyrronium bromide / budesonide MDI for the treatment of patients with moderate to… Read more . . .
-
CDMO Arcinova has added a 3P Innovation R1000 micro-dosing system at its facility in Alnwick, UK in what it called its “Fill-Inova” project, the company said. The R1000 machine includes two of 3P’s Fill2Weight filling modules,… Read more . . .
-
The Cystic Fibrosis Foundation (CFF) has awarded Synspira Therapeutics up to $14 million in additional funding for development of two Synspira candidates including SNSP113, an inhaled polycationic glycopolymer for the treatment of CF. The foundation… Read more . . .
-
Respira Therapeutics has announced that the results of Phase 1 and Phase 2a clinical studies of RT234-PAH dry powder vardenafil “support its further development as an as-needed (PRN) treatment that will allow patient-controlled dosing to… Read more . . .
-
Avalyn Pharma said that idiopathic pulmonary fibrosis (IPF) patients who received the higher dose tested in a Phase 1/2 study of the company’s AP01 pirfenidone inhalation solution “had a trend toward stabilization of lung function,”… Read more . . .
-
Armata Pharmaceuticals announced that it plans to initiate clinical development of inhaled AP-PA02, a phage cocktail the company is developing for the treatment of P. aeruginosa infections in cystic fibrosis patients. The SAD portion of the Phase… Read more . . .
-
Liquidia Technologies said that the US Patent Trial and Appeal Board (PTAB) has issued decisions on two patents related to Tyvaso treprostinil inhalation solution, which is marketed by United Therapeutics for the treatment of pulmonary arterial hypertension… Read more . . .
-
With CPhI 2020 having been converted into the virtual “Festival of Pharma” due to the COVID-19 pandemic, the CPhI Pharma Awards ceremony took place online via a live streamed event on October 13. Winners in… Read more . . .
-
Ionis Pharmaceuticals has announced data from a Phase 1 SAD/MAD study of its IONIS-ENAC-2.5Rx nebulized antisense therapy in cystic fibrosis patients demonstrating a mean 55.6% reduction of epithelial sodium channel (ENaC) messenger RNA in cystic fibrosis… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK